Evaluation of Carcinoembryonic Antigen as a Prognostic Marker for Colorectal Cancer Relapse: Insights from Postoperative Surveillance
Medical Sciences · 2025
DOI: 10.3390/medsci13040229 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Sciences, 2025. Verfasst von Stefan Titu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. Hauptthemen laut MEDLINE: Carcinoembryonic Antigen, Colorectal Neoplasms, Biomarkers, Tumor, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality worldwide. This study evaluates the predictive value of Carcinoembryonic Antigen (CEA) in identifying CRC recurrence following surgical resection.
Methods
This retrospective study was realized in the Oncology Institute in Cluj-Napoca and included 88 patients diagnosed with CRC. Clinical, demographic, and tumor-specific data were collected, including TNM staging, tumor histology. CEA levels were recorded before surgery. Receiver Operating Characteristic (ROC) analysis was performed to determine the diagnostic accuracy of CEA in predicting tumor relapse, and the sensitivity and specificity of various CEA cut-off values were assessed.
Results
Most patients presented with advanced-stage tumors (T3/T4, 80.6%). CEA levels were significantly higher in patients with lymphatic and perineural invasion and in those with metastases (mean CEA: 45.0 ng/mL for M1 vs. 13.2 ng/mL for M0, p = 0.032). ROC analysis revealed an area under the curve (AUC) of 0.877 (95% CI: 0.763–0.949). A CEA cut-off value of 11.73 ng/mL yielded 100% sensitivity and 74.5% specificity for detecting recurrence; Conclusions: CEA is a valuable non-invasive biomarker for predicting CRC relapse, with high sensitivity and acceptable specificity. Regular CEA monitoring post-surgery can facilitate early detection of recurrence, improving prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
- Department of Surgical Oncology, The Oncology Institute "Prof. Dr. Ion Chiricuta", 400015 Cluj-Napoca, Romania.
- Department of Physiology, Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
- Nanomedicine Department, Regional Institute of Gastroenterology and Hepatology, 400126 Cluj-Napoca, Romania.
- Department of Oncological Surgery and Gynecological Oncology, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Zitieren
APA
Titu, S., Ilies, R. A., Mocan, T., Irimie, A., Gata, V. A., & Lisencu, C. I. (2025). Evaluation of Carcinoembryonic Antigen as a Prognostic Marker for Colorectal Cancer Relapse: Insights from Postoperative Surveillance. Medical Sciences. https://doi.org/10.3390/medsci13040229
Vancouver
Titu S, Ilies RA, Mocan T, Irimie A, Gata VA, Lisencu CI. Evaluation of Carcinoembryonic Antigen as a Prognostic Marker for Colorectal Cancer Relapse: Insights from Postoperative Surveillance. Medical Sciences. 2025. doi:10.3390/medsci13040229
BibTeX
@article{Titu2025,
author = {Titu, Stefan and Ilies, Radu Alexandru and Mocan, Teodora and Irimie, Alexandru and Gata, Vlad Alexandru and Lisencu, Cosmin Ioan},
title = {Evaluation of Carcinoembryonic Antigen as a Prognostic Marker for Colorectal Cancer Relapse: Insights from Postoperative Surveillance},
journal = {Medical Sciences},
year = {2025},
doi = {10.3390/medsci13040229}
}
EUVIMED